Showing results (101-110 of 158) with videos related to

Sort By:
Pageof 16
JHEP Reports : Innovation in Hepatology|March 11, 2026
Efficacy and safety of GLP-1 receptor agonists in MASH with fibrosis: A systematic review and meta-analysisRafael Dos Santos Borges, Eliabe S Abreu, Giovanni Gosch Berton, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 12, 2012
Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trialM F Abdelmalek, A Humar, F Stickel, et al.
Gastroenterology|September 18, 2018
Factors Associated With Histologic Response in Adult Patients With Nonalcoholic SteatohepatitisRohit Loomba, Arun J Sanyal, Kris V Kowdley, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 7, 2020
Succinate-GPR-91 receptor signalling is responsible for nonalcoholic steatohepatitis-associated fibrosis: Effects of DHA supplementationXue-Jing Liu, Li Xie, Kuo Du, et al.
The Journal of Pathology|September 29, 2015
Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in NAFLD liversRuixin Zhu, Susan S Baker, Cynthia A Moylan, et al.
Lancet (London, England)|March 10, 2018
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen A Harrison, Mary E Rinella, Manal F Abdelmalek, et al.
The American Journal of Gastroenterology|September 14, 2019
Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase LevelsSamer Gawrieh, Laura A Wilson, Oscar W Cummings, et al.
Hepatology (Baltimore, Md.)|March 16, 2021
Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver DiseaseAnastasia-Stefania Alexopoulos, Matthew J Crowley, Ying Wang, et al.
Contemporary Clinical Trials|December 28, 2019
Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study designQuentin M Anstee, Brent A Neuschwander-Tetri, Vincent Wai-Sun Wong, et al.
Cellular and Molecular Gastroenterology and Hepatology|December 19, 2022
Hepatocyte Smoothened Activity Controls Susceptibility to Insulin Resistance and Nonalcoholic Fatty Liver DiseaseTianyi Chen, George Dalton, Seh-Hoon Oh, et al.
Pageof 16